Literature DB >> 8910854

Decomposition kinetics of cisplatin in human biological fluids.

N Nagai1, R Okuda, M Kinoshita, H Ogata.   

Abstract

Cisplatin is metabolized to high- and low-molecular mass complexes by exchanging of one or both chloride ligands with nucleophilic species. The decomposition of cisplatin and the formation of its metabolites in human biological fluids was investigated in-vitro. In nucleophile-free medium, cisplatin was decomposed by a reversible chloride ligand exchange reaction, which was dependent upon both chloride ion concentration and medium pH. The effect of pH was observed in the second-order rate constant for cisplatin re-formation, which was far smaller in neutral and alkaline media than in acidic media. In the medium containing nucleophilic species (glutathione, human albumin and globulin), cisplatin was irreversibly decomposed according to apparent first-order kinetics. The linear relationship between apparent decomposition rate constant and concentration of nucleophilic species suggested that nucleophilic species in biological fluids might react with cisplatin directly. Both high- and low-molecular mass metabolites were formed in human plasma and ascites; however, only a low-molecular mass metabolite was produced in urine. The faster decomposition of cisplatin and the greater ratio of fixed and mobile metabolites formed in plasma were mainly attributed to higher albumin concentration in plasma than in ascites and urine. The in-vitro decomposition of unchanged cisplatin and formation of high- and low-molecular mass metabolites in human biological fluids were simultaneously evaluated according to the kinetic model which combined both pathways via hydrolysis and by the direct reaction process with nucleophilic species.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8910854     DOI: 10.1111/j.2042-7158.1996.tb06002.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.

Authors:  K Hanada; K Odaka; A Kudo; H Ogata
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

2.  Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives.

Authors:  Kazuhiko Hanada; Makoto Suda; Norihito Kanai; Hiroyasu Ogata
Journal:  Pharm Res       Date:  2010-06-15       Impact factor: 4.200

3.  Caprylate-conjugated Cisplatin for the development of novel liposomal formulation.

Authors:  Imran Vhora; Nirav Khatri; Jagruti Desai; Hetal Paresh Thakkar
Journal:  AAPS PharmSciTech       Date:  2014-04-04       Impact factor: 3.246

4.  Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study.

Authors:  Marília Berlofa Visacri; Eder de Carvalho Pincinato; Graziele Baldan Ferrari; Júlia Coelho França Quintanilha; Priscila Gava Mazzola; Carmen Silvia Passos Lima; Patricia Moriel
Journal:  Daru       Date:  2017-04-24       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.